Back to the future: Bacteriophages as promising therapeutic tools

HLA

Volumn 87, Issue 3, 2016, Pages 133-140

  Domingo Calap, Pilar ^a,b   Georgel, Philippe ^a,b   Bahram, Seiamak ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Antibiotics; Bacteriophage; Drug delivery; Gene therapy; Phage display; Phage therapy; Recombinant antibodies

Indexed keywords

DRUG CARRIER; ANTIINFECTIVE AGENT; BACTERIAL VACCINE;

BACTERIAL CHROMOSOME; BACTERIOPHAGE; BACTERIUM DETECTION; HUMAN; NONHUMAN; PHAGE DISPLAY; PHAGE THERAPY; PRIORITY JOURNAL; PROPHAGE; REVIEW; VACCINE PRODUCTION; BACTERIAL INFECTIONS; BACTERIUM; BACTERIUM IDENTIFICATION; BIOSYNTHESIS; CELL SURFACE DISPLAY; CHEMISTRY; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL TYPING TECHNIQUES; BACTERIAL VACCINES; BACTERIOPHAGES; CELL SURFACE DISPLAY TECHNIQUES; DRUG CARRIERS; HUMANS; PHAGE THERAPY;

EID: 84975707204     PISSN: 20592302     EISSN: 20592310     Source Type: Journal    
DOI: 10.1111/tan.12742     Document Type: Review

References (61)

1. Comeau AM, Hatfull GF, Krisch HM, Lindell D, Mann NH, Prangishvili D. Exploring the prokaryotic virosphere. Res Microbiol 2008: 159: 306–13.
2. Pietila MK, Demina TA, Atanasova NS, Oksanen HM, Bamford DH. Archaeal viruses and bacteriophages: comparisons and contrasts. Trends Microbiol 2014: 22: 334–44.
3. Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol 2006: 24: 212–8.
4. Los M, Wegrzyn G. Pseudolysogeny. Adv Virus Res 2012: 82: 339–49.
5. Twort FW. An investigation on the nature of ultra-microscopic viruses. Lancet 1915: 186: 1241–3.
6. d’Hérelle F. Sur un microbe invisible antagoniste des bacteries dysenteriques. C R Acad Sci 1917: 165: 373–5.
7. d’Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917. Res Microbiol 2007: 158: 553–4.
8. Chanishvili N. Phage therapy –history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res 2012: 83: 3–40.
9. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001: 45: 649–59.
10. Reardon S. Phage therapy gets revitalized. Nature 2014: 510: 15–6.
11. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 2010: 28: 591–5.
12. Ptashne M. A Genetic Switch, Third Edition, Phage Lambda Revisited. Cold Spring Harbor Laboratory Press, 2004.
13. Aryee A, Price N. Antimicrobial stewardship –can we afford to do without it? Br J Clin Pharmacol 2015: 79: 173–81.
14. Reardon S. Bacterial arms race revs up. Nature 2015: 521: 402–3.
15. Thiel K. Old dogma, new tricks –21st century phage therapy. Nat Biotechnol 2004: 22: 31–6.
16. Weinbauer MG. Ecology of prokaryotic viruses. FEMS Microbiol Rev 2004: 28: 127–81.
17. Dalmasso M, Hill C, Ross RP. Exploiting gut bacteriophages for human health. Trends Microbiol 2014: 22: 399–405.
18. Melo LD, Sillankorva S, Ackermann HW, Kropinski AM, Azeredo J, Cerca N. Isolation and characterization of a new Staphylococcus epidermidis broad-spectrum bacteriophage. J Gen Virol 2014: 95: 506–15.
19. Goodridge LD. Bacteriophages for managing Shigella in various clinical and non-clinical settings. Bacteriophage 2013: 3: e25098.
20. Koskella B, Brockhurst MA. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev 2014: 38: 916–31.
21. Pal C, Macia MD, Oliver A, Schachar I, Buckling A. Coevolution with viruses drives the evolution of bacterial mutation rates. Nature 2007: 450: 1079–81.
22. Chan BK, Abedon ST. Phage therapy pharmacology phage cocktails. Adv Appl Microbiol 2012: 78: 1–23.
23. Domingo-Calap P, Sanjuan R. Experimental evolution of RNA versus DNA viruses. Evolution 2011: 65: 2987–94.
24. Domingo-Calap P, Pereira-Gomez M, Sanjuan R. Selection for thermostability can lead to the emergence of mutational robustness in an RNA virus. J Evol Biol 2010: 23: 2453–60.
25. Bikard D, Euler CW, Jiang W et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 2014: 32: 1146–50.
26. Lang LH. FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 2006: 131: 1370.
27. Hagens S, Loessner MJ. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharm Biotechnol 2010: 11: 58–68.
28. Chan BK, Abedon ST. Bacteriophages and their enzymes in biofilm control. Curr Pharm Des 2015: 21: 85–99.
29. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol 2010: 11: 28–47.
30. Azeredo J, Sutherland IW. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 2008: 9: 261–6.
31. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985: 228: 1315–7.
32. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv 2010: 28: 849–58.
33. Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004: 9: 525–9.
34. Paschke M. Phage display systems and their applications. Appl Microbiol Biotechnol 2006: 70: 2–11.
35. Hamzeh-Mivehroud M, Alizadeh AA, Morris MB, Church WB, Dastmalchi S. Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discov Today 2013: 18: 1144–57.
36. Huang JX, Bishop-Hurley SL, Cooper MA. Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother 2012: 56: 4569–82.
37. Tohidkia MR, Barar J, Asadi F, Omidi Y. Molecular considerations for development of phage antibody libraries. J Drug Target 2012: 20: 195–208.
38. Krumpe LR, Mori T. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int J Pept Res Ther 2006: 12: 79–91.
39. Hertveldt K, Belien T, Volckaert G. General M13 phage display: M13 phage display in identification and characterization of protein-protein interactions. Methods Mol Biol 2009: 502: 321–39.
40. Manoutcharian K, Gevorkian G, Cano A, Almagro JC. Phage displayed biomolecules as preventive and therapeutic agents. Curr Pharm Biotechnol 2001: 2: 217–23.
41. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 2006: 58: 1622–54.
42. Mao C, Liu A, Cao B. Virus-based chemical and biological sensing. Angew Chem Int Ed Engl 2009: 48: 6790–810.
43. Ahmadvand D, Rahbarizadeh F, Moghimi SM. Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). Curr Opin Biotechnol 2011: 22: 832–8.
44. Li K, Nguyen HG, Lu X, Wang Q. Viruses and their potential in bioimaging and biosensing applications. Analyst 2010: 135: 21–7.
45. Castel G, Chteoui M, Heyd B, Tordo N. Phage display of combinatorial peptide libraries: application to antiviral research. Molecules 2011: 16: 3499–518.
46. Cabilly S. The basic structure of filamentous phage and its use in the display of combinatorial peptide libraries. Mol Biotechnol 1999: 12: 143–8.
47. Willats WG. Phage display: practicalities and prospects. Plant Mol Biol 2002: 50: 837–54.
48. Prisco A, De Berardinis P. Filamentous bacteriophage fd as an antigen delivery system in vaccination. Int J Mol Sci 2012: 13: 5179–94.
49. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996: 2: 299–305.
50. Kolonin MG, Sun J, Do KA et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006: 20: 979–81.
51. Cortese R, Monaci P, Luzzago A et al. Selection of biologically active peptides by phage display of random peptide libraries. Curr Opin Biotechnol 1996: 7: 616–21.
52. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000: 13: 602–14.
53. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004: 2: 695–703.
54. Borrebaeck CA. Antibodies in diagnostics –from immunoassays to protein chips. Immunol Today 2000: 21: 379–82.
55. Shukra AM, Sridevi NV, Dev C, Kapil M. Production of recombinant antibodies using bacteriophages. Eur J Microbiol Immunol (Bp) 2014: 4: 91–8.
56. Bazan J, Calkosinski I, Gamian A. Phage display –a powerful technique for immunotherapy: 1. introduction and potential of therapeutic applications. Hum Vaccin Immunother 2012: 8: 1817–28.
57. Bazan J, Calkosinski I, Gamian A. Phage display –a powerful technique for immunotherapy: 2 vaccine delivery. Hum Vaccin Immunother 2012: 8: 1829–35.
58. Bakhshinejad B, Sadeghizadeh M. Bacteriophages as vehicles for gene delivery into mammalian cells: prospects and problems. Expert Opin Drug Deliv 2014: 11: 1561–74.
59. Ibraheem D, Elaissari A, Fessi H. Gene therapy and DNA delivery systems. Int J Pharm 2014: 459: 70–83.
60. Pranjol MZ, Hajitou A. Bacteriophage-derived vectors for targeted cancer gene therapy. Viruses 2015: 7: 268–84.
61. Hajitou A. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector. Adv Genet 2010: 69: 65–82.